CG Oncology (CGON) Net Cash Flow (2023 - 2026)
CG Oncology's (CGON) quarterly Net Cash Flow came in at $1.3 million in Q1 2026, up 100.58% YoY from $624684.7 in Q1 2025, and up 109.91% on a QoQ basis from -$12.6 million in Q4 2025.
CG Oncology (CGON) Net Cash Flow (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Net Cash Flow data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 100.58% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (up 78.66% YoY) and the FY2025 annual result came in at -$224.5 million, down 190.25% from the prior year.
- Net Cash Flow rose to $1.3 million in Q1 2026, from -$12.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $213.7 million in Q4 2024 to a low of -$215.6 million in Q1 2025.
- A 4-year average of -$4.2 million and a median of -$2.0 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow soared 10745.59% — and 2025, when it plunged 411.55%.
- Tracing CGON's Net Cash Flow over 4 years: stood at -$2.0 million in 2023, then soared by 10745.59% to $213.7 million in 2024, then tumbled by 105.92% to -$12.6 million in 2025, then soared by 109.91% to $1.3 million in 2026.
- The last three Net Cash Flow figures came in at $1.3 million (Q1 2026), -$12.6 million (Q4 2025), and $30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -14.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.11 Mn |
| Jun 30, 2026 | -14.11 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Mar 31, 2026 | 1.25 Mn |
| Dec 31, 2025 | -12.64 Mn |
| Dec 31, 2025 | -12.64 Mn |
| Sep 30, 2025 | 30.55 Mn |
| Sep 30, 2025 | 30.55 Mn |
| Jun 30, 2025 | -26.85 Mn |
| Jun 30, 2025 | -26.85 Mn |
| Mar 31, 2025 | -215.60 Mn |
| Mar 31, 2025 | -215.60 Mn |
| Dec 31, 2024 | 213.66 Mn |
| Dec 31, 2024 | 213.66 Mn |
| Sep 30, 2024 | 18.25 Mn |
| Sep 30, 2024 | 18.25 Mn |
| Jun 30, 2024 | -52.31 Mn |
| Jun 30, 2024 | -52.31 Mn |
| Mar 31, 2024 | 69.20 Mn |
| Mar 31, 2024 | 69.20 Mn |